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Approximately 2.7 million Americans have active Hepa-
titis C infection. Combination therapy with ribavirin and
interferon alfa-2b has emerged as the treatment of choice
for Hepatitis C. OBJECTIVES: To determine if the pre-
scribing of combination therapy differed among ethnic
groups in Hepatitis C-infected members during calendar
year 1999 in a Medicaid MCO. METHODS: Hepatitis
C-infected patients were identified from a database of
continuously enrolled members of an inner-city Medicaid
MCO in Philadelphia using ICD-9 codes indicative of
Hepatitis C (070.41, 070.44, 070.51, 070.54, 571.40,
571.41, V02.60, V02.62). From this population, mem-
bers who received combination therapy with ribavirin
and interferon alfa-2b were identified and demographic
information was obtained. Variation in the prescribing of
combination therapy among ethnic groups was assessed
using a Chi-square test. RESULTS: From a cohort of
73,869 members, 395 members (0.535%) had an ICD-9
code for Hepatitis C. Of those, 60 members had phar-
macy claims for combination therapy during 1999. These
members aged from 23 to 64 years (mean age  45.0 yrs;
SD  7.6). Based on the ethnic distribution of the 395
members with an ICD-9 code for Hepatitis C, 8.4% (16/
191) of African-Americans were prescribed combination
therapy compared with 23% (28/122) of Caucasians,
22.7% (15/66) of Latinos and 14.3% (1/7) of Asian-
Americans. A statistically significant difference in the pre-
scribing of combination therapy was noted among ethnic
groups (p  0.05). CONCLUSIONS: Within this Medic-
aid MCO, a disproportionately low percentage of Afri-
can–American members received combination therapy
for Hepatitis C during 1999. It is unknown whether this
was due to a disproportionate number of contraindica-
tions in this group, inequitable prescribing habits of phy-
sicians, cultural barriers preventing consent for treat-
ment, or noncompliance with obtaining the medication.
Further investigation is needed to determine why this dis-
parity exists so that differences in treatment among eth-
nic groups may be minimized.
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INTRODUCTION: Medicare is required to set outlier
threshold so that outlier payments are between 5 and 6
percent of total DRG payments to offset extraordinarily
high-cost cases. Severe sepsis (SS) is a condition affecting
patients in many DRGs. High mortality and resource use
in SS patients increases the likelihood of reimbursement
under the outlier mechanism. We explore the role of out-
lier payments for SS in Medicare. METHODS: We exam-
ined all 1999 Medicare discharges age 65 in prospec-
tive payment hospitals. Cost, reimbursement, and outlier
payments were identified for each discharge. SS was iden-
tified by the presence of ICD-9-CM codes for acute organ
failure and bacterial or fungal infection. DRGs were clas-
sified into six groups by post-operative status (medical
and surgical) and by frequency of SS (high risk, high vol-
ume, remaining). RESULTS: Of 9,248,277 records,
384,680 (4%) were reimbursed through the outlier mech-
anism, reflecting 6% of total payments. SS patients repre-
sent 25% of all outliers, with an average cost per outlier
case of $44,724. The average cost for non-sepsis outliers
per case is $35,098. Twenty-two percent of all sepsis
cases are reimbursed as outliers. While overall cases are
reimbursed at 95% of reported costs, SS cases are reim-
bursed at only 85% of costs. SS outliers are reimbursed
at only 70% of reported costs with especially low reim-
bursements for high volume medical SS outlier cases
(54%). Overall, SS high risk medical and surgical cases
are reimbursed at higher levels (103% and 78% respec-
tively). CONCLUSIONS: While severe sepsis cases are
only 4.7% of all Medicare discharges, almost one in four
are outliers. Current outlier payments do not adequately
compensate for the cost of care of most SS patients.
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BACKGROUND: In January 1998, Regence BlueShield,
a 1.2 million-member health plan, implemented a novel
formulary submission process intended to improve clini-
cal decision-making. The process requires pharmaceutical
manufacturers to submit dossiers that include clinical and
health outcomes data as well as an economic model that
will demonstrate the impact of introducing the product
to the health plan. Since implementation, the process has
not been evaluated. OBJECTIVE: To evaluate the scope
and content of submission dossiers received from January
1998 to June 2000. METHODS: All dossiers received
from January 1998 to June 2000 were collected and re-
viewed. They were evaluated for compliance with the Re-
gence Formulary Submission Guidelines. Data were en-
tered into a spreadsheet for analysis. RESULTS: A total
of 50 dossiers were reviewed. 25 (50%) were received in
year 1, 16 (32%) in year 2, and 9 (18%) in the first six
months of year 3. An economic model was provided in
31 dossiers, increasing from 55% to 78% of dossiers
over the three years. Only 10 models were cost-effective-
ness analyses. The remaining models were budget impact
analyses. Complete clinical information was included in
48%, 63% and 78% of submissions in years 1, 2 and 3
respectively. Dossiers were prepared by one of three
sources: Staff at the manufacturer’s headquarters (68%),
an outside vendor (10%) or a local manufacturer’s repre-
sentative (22%). Unpublished studies, which were specif-
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ically requested, were included in 18 dossiers, and off-
label information was included in 7. Of the 50 products
submitted, 24 (48%) were added to Formulary. CON-
CLUSIONS: Compliance with the guidelines has im-
proved over the past 30 months. Overall, a majority of
the submissions included complete clinical information
and some type of economic analysis. There remains,
however, significant opportunity for improvement, par-
ticularly in the presentation of economic evaluation data
and the dissemination of unpublished studies.
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Obesity is now recognized as a chronic health condition
instead of a cosmetic or lifestyle issue. Orlistat and
sibutramine are effective weight-loss/weight-maintenance
agents. Insurers argue that the high prevalence of obesity
(i.e., body mass index (BMI)3 30kg/m2), questionable
long-term health benefits, and cost of these drugs make it
unfeasible to cover them. Proponents claim decreases in
obesity’s comorbidities would offset acquisition costs.
OBJECTIVES: To provide evidence for a rational reim-
bursement policy for pharmacological treatments of obe-
sity in adults. METHODS: A Markov decision analytic
model was used to evaluate the cost-effectiveness of orlistat
(120mg TID) and sibutramine (5–20mg QD) relative to
diet and exercise alone. The model analyzed a hypothetical
population of obese, but otherwise healthy 30 year olds
over their lifetime. Estimates of efficacy and tolerance were
derived from a meta-analysis of randomized, placebo-con-
trolled trials of orlistat and sibutramine. The Framingham
Study was used to derive risk-adjusted equations for the in-
cidence of hypertension, dyslipidemia, and DM as well as
the incidence of CV events, CV-attributable death, and
non-CV death. Equations were adjusted for known risk
factors, including BMI. The reference case analysis used the
societal perspective and included both direct and indirect
costs (discount rate, 3%). Costs were derived from the liter-
ature and inflated to year 2000 Canadian dollars (CDN$).
Utilities were derived from a Canadian health survey and
from the literature. Decision index: incremental cost per
quality adjusted life year ($/QALY). A Monte Carlo simu-
lation will be used to perform a sensitivity analyses around:
estimated weight-loss, estimated dropout rates, estimated
weight regain, cost of treatment, and major clinical events.
RESULTS: Results for the base case (i.e., societal view-
point) and third party payer (i.e., Ministry of Health) per-
spectives will be presented and discussed. Emphasis will be
placed on the decision model approach for informing for-
mulary decisions on “lifestyle” drugs.
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Cost-utility analysis is rapidly becoming the standard
pharmacoeconomic measure in oncology. In a recent re-
port (JCO, 2000;18:3302), data from 40 published cost-
utility studies were presented in a league table format.
Most of those studies utilized nurses or physicians as
proxies for the pt. in determining utility. OBJECTIVE:
To determine if there is a difference between utility scores
obtained from metastatic breast cancer pt. and oncology
nurses. METHODS: Using eight modified Markov mod-
eled health states (Pharmacoeconomics, 1996; 60:504)
describing metastatic breast cancer; the standard gamble
procedure was utilized to obtain utility scores from 45
patients and 57 oncology nurses. Utility values were mea-
sured on a scale between 0.0 and 1.0. Independent t-tests
were used to test for differences between groups using an
alpha level of 0.05 (2-sided). RESULTS: Significant dif-
ferences were found on all eight modeled health states:
CONCLUSION: These results show that patients have a
higher utility for health than perceived by nurses. These
data leads to the question of whose utility values should
be used for cost-utility analysis in oncology.
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Modeled Disease State
Mean Utility
Score (SD)
Patients/Nurses
(n  45; n  57)
P
Value
95%
Confidence
Intervals
Partial Response (PR) .84 (.11)/.71 (.22) .0001 .06–.20
PR with Severe
Peripheral Edema .78 (.17)/.63 (.24) .0001 .08–.24
PR with Severe
Peripheral Neuropathy .76 (.13)/.56 (.24) .0001 .12–.28
Before Second Line
Treatment Begins .73 (.16)/.59 (.22) .0001 .06–.22
Stable Disease .72 (.15)/.54 (.22) .0001 .11–.26
Late Progressive Disease .63 (.18)/.45 (.25) .0001 .10–.27
Terminal Disease .40 (.26)/.19 (.21) .0001 .13–.31
Sepsis .39 (.25)/.20 (.23) .0001 .09–.28
